Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Rosenberg AJ, Agrawal N, Juloori A, Cursio J, Gooi Z, Blair E, Chin J, Ginat D, Pasternak-Wise O, Hasina R, Starus A, Jones FS, Izumchenko E, MacCracken E, Wolk R, Cipriani N, Lingen MW, Pearson AT, Seiwert TY, Haraf DJ, Vokes EE.
Rosenberg AJ, et al. Among authors: ginat d.
JAMA Oncol. 2024 Jul 1;10(7):923-931. doi: 10.1001/jamaoncol.2024.1530.
JAMA Oncol. 2024.
PMID: 38842838
Clinical Trial.